| How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study. | |
| | |
MedLine Citation:
|
PMID: 20609184 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Anemia is a common clinical problem in end-stage renal disease (ESRD). Despite adequate erythropoiesis-stimulating agent (ESA) supplementation, some ESRD patients still have suboptimal hemoglobin levels, and iron deficiency and inflammation are recognized as the two most common causes. Hepcidin, a newly discovered key regulator of iron homeostasis, is found to be accumulated in ESRD. As it controls iron uptake and release, better reflecting real-time iron demand and availability, hepcidin might become a target in the management of iron deficiency and ESA resistance in dialysis patients. For their pleiotropic functions apart from lipid-modulation, statins are also used as anti-inflammatory or immune-modulating agents. In this study, we applied simvastatin for the purpose of influencing serum prohepcidin level in a group of maintenance hemodialysis patients. Thirty-three ESRD patients undergoing hemodialysis were enrolled and assigned to experimental and hemodialysis control groups according to their lipid profile. Nineteen healthy adults were chosen as a normal control group. The subjects in the experimental group took 20 mg simvastatin orally per night for eight weeks, and those in the hemodialysis control group took no statins or any other lipid-modulating drugs. Before and after the experiment, the serum prohepcidin concentrations, plasma IL-6, and serum C-reactive protein (CRP), ferritin, hemoglobin, albumin, total cholesterol, glycerinate, and LDL and HDL cholesterol levels were determined. Of the 33 hemodialysis patients, the serum prohepcidin concentration was (175.8 +/- 52.9) ng/mL, significantly higher than that in the normal control group (149.5 +/- 24.2) ng/mL (P = 0.048). In the experimental group, the serum prohepcidin level was (156.7 +/- 51.9) ng/mL before treatment, and (190.6 +/- 49.6) ng/mL after eight weeks (P = 0.127). In the hemodialysis control group, the serum prohepcidin level was (190.6 +/- 49.6) ng/mL at the beginning, and (193.5 +/- 36.0) ng/mL after eight weeks (P = 0.728). In the experimental group, after taking simvastatin for eight weeks the serum total cholesterol and triglyceride levels had lowered by 18.6% (P = 0.004) and 55.1% (P = 0.007), respectively. The plasma IL-6, serum CRP, ferritin, hemoglobin, albumin, and LDL and HDL cholesterol levels in both the hemodialysis group remained unchanged. According to our preliminary study, eight weeks of 20 mg simvastatin did not significantly change the serum prohepcidin, high-sensitive CRP, or IL-6 concentrations in the group of maintenance hemodialysis patients. |
| | |
Authors:
|
Xiang-Yang Li; Ju-Ping Chang; Zhuo-Wa Su; Jiu-Hong Li; Bo-Shen Peng; Sheng-Lang Zhu; An-Ji Cai; Jun Zhang; Ying Jiang |
Related Documents
:
|
1384624 - The physiology of iron, transferrin, and ferritin. 6496174 - Iron metabolism and "sports anemia". i. a study of several iron parameters in elite run... 3781354 - Relationship between maternal and infant iron stores: 1. full term infants. 3566864 - Bioavailability of bi- and trivalent oral iron preparations. investigations of iron abs... 2365024 - Increased serum osteocalcin levels in elderly females with vitamin d deficiency. 4339354 - Daily variation in concentration of cortisol in plasma in intact and hypophysectomized ... |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy Volume: 14 ISSN: 1744-9987 ISO Abbreviation: Ther Apher Dial Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-07-08 Completed Date: 2010-10-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101181252 Medline TA: Ther Apher Dial Country: Australia |
Other Details:
|
Languages: eng Pagination: 308-14 Citation Subset: IM |
Affiliation:
|
Department of Nephrology, Nanshan Hospital, Guangzhou Medical College, Guangdong, China. li_lee95@yahoo.com.cn |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antimicrobial Cationic Peptides / blood* C-Reactive Protein / metabolism Case-Control Studies Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology* Interleukin-6 / blood Kidney Failure, Chronic / therapy* Male Middle Aged Protein Precursors / blood* Renal Dialysis* Simvastatin / pharmacology Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antimicrobial Cationic Peptides; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Interleukin-6; 0/Protein Precursors; 0/prohepcidin; 79902-63-9/Simvastatin; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of eicosapentaenoic Acid supplementation on immunoglobulin a nephropathy.
Next Document: Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients.